About Us

About Us : Leadership : Management

Steven Tregay, Ph.D.

Founder, President and CEO

Prior to founding FORMA, Steven Tregay was a Managing Director for the $200M Novartis Option Fund. He led the fund’s investments in and served on the Board of Directors of FORMA Therapeutics, Adenosine Therapeutics (acquired by Clinical Data: FRX) and Cequent Pharmaceuticals (acquired by Marina Biotech: MRNA). Prior to joining the venture group, he was the Executive Director and Head of Strategic Alliances-Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. He managed a team who were responsible for identification, negotiation and management of collaborations for the oncology and ophthalmology disease areas and all the technology areas. Prior to Novartis, he had roles in business development at Array BioPharma and research.

Dr. Tregay is co-founder and Chairman of the Board of Compass Therapeutics and serves as a Board Member of LabCentral. He received his Ph.D. and M.S. in organic chemistry from Harvard University and a B.S. from Davidson College.

 

John Hohneker, M.D.

Executive Vice President and Head of Research and Development

Dr. Hohneker joins FORMA with over 25 years of drug development experience in the pharmaceutical industry across a broad range of therapeutic areas, including oncology, immunology, dermatology, rheumatology, and organ transplantation. He has played a critical role in advancing therapeutics from preclinical through health authority approval, including 17 drug launches. Dr. Hohneker held various leadership positions at Novartis from 2001 to 2015. Most recently, as Senior Vice President and Global Head of Development, Immunology and Dermatology, where he was responsible for the global development of the immunology, rheumatology, and dermatology product pipelines including the recent approvals and launches of Cosentyx®, Xolair® and Ilaris®. Previously he also served as Senior Vice President of U.S. Oncology Clinical Development and Medical Affairs where he played a key role in the development, approval, and/or commercialization of several important oncology products such as Gleevec®, Tasigna®, Zometa®, Afinitor®, and Exjade®. Prior to joining Novartis, Dr. Hohneker spent approximately 11 years at Glaxo Wellcome and its legacy company Burroughs Wellcome in various roles of increasing responsibility, including Worldwide Therapeutic Head, Director, Oncology Clinical Development and led the approval of Navelbine®. He has also served on the research committee of the American Society of Clinical Oncology and the Institute of Medicine’s Cancer Policy Forum. He also held a faculty position at the University of North Carolina School of Medicine at Chapel Hill, N.C.

Dr. Hohneker received a bachelor’s degree in chemistry from Gettysburg College, Gettysburg, PA., and M.D. from the University of Medicine and Dentistry of New Jersey, Rutgers Medical School (Robert Wood Johnson Medical School), Piscataway, N.J. He completed his internship and residency in internal medicine and his fellowship in medical oncology all at the University of North Carolina Hospitals at Chapel Hill, N.C.

Rob Sarisky, Ph.D.

Chief Business Officer

Dr. Sarisky brings to FORMA over 25 years of oncology business and scientific expertise. He most recently served as Vice President of Oncology Business Development and Licensing within Janssen Pharmaceuticals, a Johnson & Johnson company. Prior to joining Janssen Pharmaceuticals, Dr. Sarisky held positions of Vice President of External Research and Early Development within Johnson & Johnson, Sr. Director of Immunology Research at Centocor, and Director of Virology at GlaxoSmithKline Pharmaceuticals. Dr. Sarisky received his B.S. degree in Biology from the University of Scranton, a Ph.D. in Genetics from the Pennsylvania State University College of Medicine, completed his postdoctoral training at the Johns Hopkins School of Medicine, and holds an M.B.A. in Marketing from Lehigh University. He has authored more than 120 publications and patents and served on the Editorial Board for two scientific journals. He has been active in the academic community by serving on the University of Pennsylvania Executive Advisory Committee for the HHMI Graduate Training in Medical Sciences, the University of Miami Innovation Corporate Advisory Council, the University of North Carolina Innovation Transfer and Development Initiative, adjunct Professor for Drexel University School of Medicine and an Advisory Board member for Indiana University’s Biotechnology Program.

 

Mary Kachinsky CPSM, C.P.M.

Vice President, Strategic Sourcing

Joining FORMA in 2015, Mary brings over 25 years’ experience as a strategic partner and business leader in the research, development and manufacturing procurement functions spanning across the pharmaceutical, biotech and consumer electronics industries. Prior to her current role at FORMA, Mary worked at Cubist Pharmaceuticals where she launched the Strategic Sourcing organization in 2011, with a robust change management strategy requiring engagement and participation across the enterprise. Under Mary’s leadership, the Sourcing organization successfully supported Cubist’s growing portfolio and clinical trials pipeline through cost savings initiatives and efforts to build a sustainable supply network. Previous to Cubist, Mary held various leadership positions for 8 years at Pfizer, where she most recently led the Global Scientific Materials organization and supported the outsourcing of clinical trials at Pfizer Global R&D. She also held senior leadership positions at Genzyme, Waters, and Bose Corporation.

Mary is an Executive Member of Linking Leaders Clinical Outsourcing Roundtable and is a member of the Bio-Supply Management Alliance Board of Advisors. She received the 2013 NESCON Supply Chain Hall of Fame Award and the 2009 Harry J. Graham Award from the Purchasing Management Association of Boston (PMAB), affiliate of ISM, for her generous volunteer work. In addition, Mary is an Advisor on the PMAB Board of Directors, where she has also served as President. She is a Certified Professional in Supply Management (CPSM) and a Lifetime Certified Purchasing Manager (C.P.M.). Mary earned her Master of Science in Management from the Lally School of Management, Rensselaer Polytechnic Institute and her Bachelor of Arts, magna cum laude, from the Carroll School of Management, Boston College.

 

Suresh Babu, Ph.D.

Vice President, Chemistry, Manufacturing and Controls

Dr. Babu brings over 25 years of small biotech and large multinational pharmaceutical company experience to his role as Vice President of CMC at FORMA. With his technical expertise in pre-formulation and first in human dosage formulations, bio-enhancement technologies and life-cycle product development, Dr. Babu's commitment to a new drug discovery paradigm is derived from this expansive background combined with the buildout of high functioning scientific teams. Throughout his career he has provided leadership to manage internal and external sourcing strategies as well as responsibility for CMC sections of regulatory submissions. Prior to FORMA, Dr. Babu most recently served as the Vice President of CMC at Synta Pharmaceuticals, and previous to that post, held various scientific leadership roles in Pfizer Global R&D, Warner-Lambert/Parke-Davis, and Johnson and Johnson's CMC organizations. Dr. Babu received his Bachelor of Science in Pharmacy along with a Certification of Pharmacy Manufacturing from the University of Bangalore, India. He then received his Ph.D. in Pharmaceutics from the University of Connecticut, CT, where he also serves as a member of the Advisory Board for the School of Pharmacy.

 

Christopher Dinsmore, Ph.D.

Vice President, Medicinal and Computational Chemistry

Prior to joining FORMA in 2013, Dr. Dinsmore led a distinguished 19 year career at Merck & Co., Inc. As Executive Director of Discovery Chemistry and founding member of the Merck Research Laboratory in Boston, he helped build highly integrated and collaborative new approaches to discovery research. During his tenure at Merck, Chris held various positions of scientific and managerial leadership and gained a broad background in the identification of therapeutics for oncology, cardiovascular, Alzheimer’s, asthma and rheumatoid arthritis diseases. Chris’s efforts led to the discovery and advancement of seven development compounds evaluated in clinical trials, and several preclinical development candidates. He served on several Joint Steering Committees for research partnerships with external organizations, and was a member of Merck’s committee responsible for evaluating oncology in-licensing opportunities. He has co-authored over 50 publications in chemistry and drug discovery, and is a co-inventor on nearly 60 patents. Dr. Dinsmore received his Ph.D. in organic chemistry from the University of Minnesota, Minneapolis, and was a Postdoctoral Fellow at Harvard University.

 

Lee Merrill, MBA

Vice President, Human Resources

Lee brings over 20 years of diverse experience in Human Resources with core competencies in the areas of employment, employee relations, organizational development, business partnering, and compensation. His skills include the ability to engage the business environment with a strong strategic and tactical approach while maintaining a high degree of concern for people and results. He has an extensive recruitment background both internally to companies and as the head of his own recruitment firm. Lee has served on several panel discussions with senior HR practitioners and is well thought of in the industry. Over the most recent years, he has successfully led HR departments at Molecular Insight Pharmaceuticals, Targanta Therapeutics and Acambis. He has established start-up HR departments supporting multiple sites in both the private and public sectors internationally. Lee has significant experience in leadership training and is an active co-chair for a successful HR Biotech networking group with active participation from over 50 local biotech and pharmaceutical companies. He obtained his MBA from Babson College and his undergraduate degree from the University of Vermont.

 

Karoline Shair, Ph.D., J.D.

Vice President, Legal and Chief Intellectual Property Counsel

Karoline brings over 20 years’ global experience in the biotechnology and pharmaceutical sector. Prior to joining FORMA, Karoline held various leadership positions at Millennium and Takeda from 2004 to 2016, most recently as Vice President and IP Region Head at Takeda Pharmaceuticals International Co. in Cambridge, Massachusetts, where she was responsible for global IP support for Oncology research, development and commercial activities as well as general IP support for on-site research and development. During that time, she provided strategic IP leadership leading local and global teams and working extensively with cross-functional teams to build, protect and enforce patent portfolios in oncology and inflammation as well as provide support for corporate development and in-licensing transactions. Prior to Millennium, Karoline gained relevant bench experience designing novel drug candidates at Sloan Kettering Institute for Cancer Research and Ariad Pharmaceuticals, as well as began her foundational training in IP at Choate, Hall & Stewart and Vertex in various legal roles.

Karoline received a bachelor’s degree with honors in chemistry from Bryn Mawr College, Bryn Mawr, PA, a Ph.D. in chemistry from Yale University, New Haven, CT and a J.D. from Boston College Law School, Newton, MA. Karoline is a member of the Massachusetts Bar and a registered patent attorney with the United States Patent and Trademark Office.

 

Duncan Walker, Ph.D.

Vice President, Pharmacology and Early Development

Prior to joining FORMA, Duncan led the Oncology, Cellular and Translational Medicine team at Array BioPharma and notably was responsible for advancing its ARRY-520 clinical program in multiple myeloma. Prior to that, he was Vice President, Discovery Biology at Sunesis Pharmaceuticals and Vice President, Oncology Research at Roche, and he also held various scientific and managerial leadership positions at Glaxo Wellcome. Duncan has co-authored 30 publications and patents and has served as a member of various scientific advisory boards. Duncan received his Ph.D. in Biochemistry and Molecular Biology from Washington University in St. Louis and was an HHMI Research Fellow at University of Colorado Health Science Center in Denver.

 

Mary Wadlinger

Chief Human Resources Officer

Mary Wadlinger brings over 25 years of experience as a strategic human resources leader in biotechnology and global biopharmaceuticals as well as consumer and nonprofit organizations. For the past 11 years, Mary has served at Millennium Pharmaceuticals, Inc., a subsidiary of Takeda Pharmaceutical Company Limited, in Cambridge, Mass., most recently as Vice President Human Resources. Prior to joining FORMA, Mary Wadlinger held numerous human resource leadership positions at Millennium, where she oversaw the HR business partners group, employee engagement, learning & development, talent and performance management, succession planning, compensation, and benefits. Millennium is known for its strong culture and has been recognized in Fortune and The Boston Globe as a “Great Place to Work.” Before entering the biotech sector, Mary served as Vice President, Human Resources and Customer Relations for a consumer goods internet retailer and led process improvement and auditing for a retail holding company. Mary has served as a member of WOMEN Unlimited’s President Counsel, Executive Development Roundtable at Boston University, HR Leadership Forum, and other not-for-profit and HR organizations.

 

Helen M. Boudreau

Chief Financial Officer

Joining FORMA Therapeutics in 2014, Helen brings over 25 years' global experience in finance, strategy and operations within the pharmaceutical, commercial banking and consumer sectors. From 2008 to 2014, she had served at Novartis, most recently as Chief Financial Officer, Novartis Corporation, where she was responsible for treasury, tax, insurance, investor relations, the Finance Shared Service Center and financial management for corporate entities within the United States. Previously, Helen served as Vice President, Investor Relations and was the Global Chief Financial Officer for Novartis Oncology. Prior to joining Novartis, she held various leadership positions for 10 years at Pfizer, where she last served as Vice President, Finance for the Customer Business Unit and Commercial Operations. Previously at Pfizer, Helen spent eight years in R&D in roles of increasing responsibility for Global R&D Finance, Research Finance and Procurement, Financial Planning & Strategic Analysis, and Strategic Management. Before joining the pharmaceutical sector, Helen gained expertise in strategic planning in the restaurant division of PepsiCo/YUM Brands, was an Engagement Manager at McKinsey & Co and was a Commercial Banking Officer at Bank of America. Helen received a B.A. in economics, summa cum laude, from the University of Maryland and an MBA with honors from the Darden School of Business at the University of Virginia, where she is a member of the Corporate Advisory Board.

 

Jim Winkler, Ph.D.

Vice President, Discovery and Translational Biology

Prior to joining FORMA, Jim has held various leadership positions at McNeil Pharmaceuticals, GlaxoSmithKline, Array Biopharma and Arvinas. Most recently at Arvinas, Jim was responsible for platform advancement and the discovery of therapeutic compounds targeting specific proteins for degradation. From 2002 through 2013, at Array Biopharma, Jim provided leadership for teams working in drug discovery, translational research and clinical development, as well as having managed several collaborations with multinational pharmaceutical firms. His contributions included building a pipeline of development drugs with over twelve having advanced toward Phase II or III studies to date.

Jim received a bachelor’s degree in biochemistry from Princeton University, Princeton, New Jersey, and a Ph.D. in pharmacology from Medical College of Pennsylvania, Philadelphia, Pennsylvania. He completed a post-doctoral fellowship in molecular pharmacology with Stanley Crooke, M.D., Ph.D., at Smith Kline and French Laboratories. To date, he has authored more than 120 patents, peer-reviewed manuscripts, reviews and book chapters, and serves as Secretary and Board Member of the Cancer Molecular Therapeutics Research Association.

 
Steven Tregay, Ph.D.
John Hohneker, M.D.
Rob Sarisky, Ph.D.
Helen M.  Boudreau
Mary Wadlinger
Suresh Babu, Ph.D.
Christopher Dinsmore, Ph.D.
Mary Kachinsky CPSM, C.P.M.
Lee Merrill, MBA
Karoline Shair
Ph.D., J.D.
Duncan Walker, Ph.D.
Jim Winkler, Ph.D.